Publications by authors named "G W Bos"

Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that the spatial organization of immune cells in tumor microenvironments is a significant parameter for impacting disease progression as well as therapeutic responses, an improved understanding of tumor-infiltrating NK cells and their location within tumor contextures is needed to improve the design of effective NK cell-based therapies. In this study, we developed a multiplex immunohistochemistry (mIHC) antibody panel designed to quantitatively interrogate leukocyte lineages, focusing on NK cells and their phenotypes, in two independent breast cancer patient cohorts (n = 26 and n = 30).

View Article and Find Full Text PDF

Standard citation-based bibliometric tools have severe limitations when they are applied to periods in the history of science and the humanities before the advent of now-current citation practices. This paper presents an alternative method involving the extracting and analysis of to map and analyze links between scholars and texts in periods that fall outside the scope of citation-based studies. Focusing on one specific discipline in one particular period and language area-Anglophone philosophy between 1890 and 1979-we describe a procedure to create a by identifying, extracting, and disambiguating mentions in academic publications.

View Article and Find Full Text PDF
Article Synopsis
  • * Targeting inhibitory receptors like KIRs and NKG2A may enhance NK cell function, allowing for better anti-tumor responses, especially in solid tumors where current therapies struggle.
  • * The review discusses various strategies for modifying these inhibitory pathways while balancing effective activation of NK cells with safety considerations for patients.
View Article and Find Full Text PDF
Article Synopsis
  • The HOVON 104 study involved 50 patients receiving bortezomib-dexamethasone therapy followed by autologous stem cell transplantation (ASCT), with 35 patients undergoing the transplantation.
  • The study reported a 5-year overall survival rate of 73% and progression-free survival of 52% for all patients, while those who received ASCT had even better outcomes, with 5-year overall survival at 91% and progression-free survival at 68%.
  • Notably, the study indicated a 60% complete response in organ function after ASCT, with cardiac responses stabilizing after 2 years and renal responses gradually improving, achieving completeness in 61% of affected patients by 5 years.
View Article and Find Full Text PDF